<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326829</url>
  </required_header>
  <id_info>
    <org_study_id>QL1604-201</org_study_id>
    <nct_id>NCT04326829</nct_id>
  </id_info>
  <brief_title>QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors</brief_title>
  <official_title>A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate Efficacy and Safety of QL1604 Monotherapy for the Treatment of Unresectable or Metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability-high (MSI-H) Solid Tumors That Failed to Respond to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with previously-treated locally-advanced or metastatic mismatched
      repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC)
      and other solid tumors will be treated with QL1604 monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by independent radiological review committee (IRRC) per RECIST Version 1.1 and iRECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by the investigators per RECIST Version 1.1 and iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month PFS rate</measure>
    <time_frame>the proportion of subjects who have time interval over 6 months between the first dose and disease progression or death</time_frame>
    <description>6-month progression-free survival (PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month OS rate</measure>
    <time_frame>from the date of first dose until the date of 6-month</time_frame>
    <description>6-month overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by independent radiological review committee (IRRC) per RECIST v1.1 and iRECIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by the investigators per RECIST v1.1 and iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose until the date of death from any cause， assessed up to 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Advanced Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>QL1604 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1604</intervention_name>
    <description>QL1604, IV infusion</description>
    <arm_group_label>QL1604 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteer to participate in this clinical study; completely understand and know this
             study as well as sign the informed consent form (ICF);

          2. Age ≥ 18 years and ≤ 80 years when ICF is signed;

          3. Histologically confirmed locally advanced or metastatic dMMR or MSI-H status
             colorectal carcinoma or other malignant solid tumors;

          4. At least one measureable lesion as defined per RECIST Version (v) 1.1 ;

          5. Subjects who have disease progression or intolerable reactions after the currently
             available standard anti-cancer treatment previously received or refused prior cancer
             therapy regimen(s) ;

          6. Subjects must provide tumor tissues and blood samples for the determination of MSI,
             tumor mutational burden (TMB), PD-L1 expression level;

          7. Eastern Cooperative Oncology Group performance status of 0 or 1;

          8. Life expectancy of greater than 12 weeks;

          9. Adequate hematologic and organ function;

         10. Female subjects who are not pregnant or breastfeeding

         11. Male and female subjects able to have children must agree to use highly effective
             method of contraception throughout the study and for at least 120 days after last
             dose.

        Exclusion Criteria:

          1. Known hypersensitivity to any monoclonal antibody, QL1604 and/or any of its
             excipients;

          2. Subjects with known central nervous system (CNS) metastasis;

          3. Active autoimmune disease that has required systemic treatment in past 2 years,
             replacement therapy is acceptable;

          4. Subjects with major cardiovascular and cerebrovascular diseases;

          5. Subjects with uncontrollable pleural effusion, pericardial effusion or ascites;

          6. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg
             daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days
             before the first dose of study drug;

          7. Subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy,
             other anti-tumor treatments, or participating in other clinical studies is less than 4
             weeks before the first administration of investigational product;

          8. Subjects who have not recovered to CTC AE Grade 1 or better from related side effects
             of any prior antineoplastic therapy;

          9. Received a live vaccine within 30 days of planned start of study medication;

         10. Infection with human immunodeficiency virus (HIV), HAV, HBV and HCV;

         11. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1
             (anti-PD-L1), anti-PD-L2 agent, cytotoxic lymphocyte associated protein-4 (CTLA-4),
             OX-40, CD137;

         12. Known psychiatric or substance abuse disorders that would interfere with the
             requirements of the study;

         13. History or current evidence of any condition, therapy, or laboratory abnormality, that
             might confound the results of the trial, or interfere with the participant's
             participation for the full duration of the study, or investigators/sponsor consider
             the subjects are not suitable for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shunjiang Yu, CMO</last_name>
    <phone>0531-83129659</phone>
    <email>shunjiang.yu@qilu-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weijian Guo, Professor</last_name>
    <phone>021-64175590</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>2000 32</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weijian Guo, Professor</last_name>
      <phone>021-64175590</phone>
    </contact>
    <investigator>
      <last_name>Weijian Guo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Bi, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

